Nanopharm Ltd., an Aptar Pharma company, is a world leading specialist contract research organization (CRO) offering product design and development services for orally inhaled and nasal drug products (OINDPs). Nanopharm helps its clients navigate the scientific, technical and regulatory challenges in developing nasal and respiratory drug products from discovery through to clinical investigations. Its service offerings provide the most efficient path to success for its clients by providing an integrated drug development service covering:
- Advanced materials characterization
- Device and formulation development
- Inhaled biopharmaceutics
These early phase services aid successful product development by understanding how material properties and processing conditions influence product functionality and therefore reduce risks and expedite drug development timelines. The proprietary technology platforms for advanced materials characterization, formulation & device development and in-silico modelling of in vivo behavior have provided Nanopharm a technical competitive edge, helping it become an international market leader. More recently, Nanopharm’s SmartTrack™ platform gained international recognition at CPhI 2019 as an innovative platform allowing developers of generic OINDPs to accelerate their programs and potentially circumvent clinical end-point studies.
For more information visit: www.nanopharm.co.uk and www.pharma.aptar.com
Nanopharm, an Aptar Pharma Company
Cavendish House
Hazell Drive
Newport NP10 8FY
United Kingdom
+44 (0) 1633 504 776
nanopharm.co.uk
enquiries@nanopharm.co.uk
API Characterization
From drug discovery all the way to commercial launch, understanding the physicochemical properties and selecting the correct APIs is critical to delivering the product performance. Interactions of the API with each other, excipients, the device, and the human body need to be characterized pre- and post-formulation, and post-aerosolization. More Info
Analytical Method Development
Developing precise, robust, accurate and clinically relevant methods ensures that you can both control CQA and expedite product development by being able to correlate in vitro performance with clinical data. Nanopharm has proprietary aerosol collection systems and test methods accepted by regulators. More Info
Formulation Development
Utilizing robust analytical methods and a solid, scientific foundation of the input materials accelerates formulation development. Nanopharm can develop formulations for DPIs, pMDIs (including with green propellants), nasal sprays (powder and liquid) and soft-mist inhalers. More Info
Device & Aerosol Testing
Whether developing a generic or innovator product, you need to test its performance as part of device and or formulation design and development. Nanopharm can offer standard and proprietary solutions to help you achieve the target product profile. More Info
Computational Pharmaceutics & Modelling
Clinical trials are expensive and time consuming. Nanopharm’s CPM team has built models to predict PK and regional lung/nasal deposition from in vitro data, derisking the necessary clinical studies and avoiding the need for others (e.g., clinical end-point PD for bioequivalence). Alternative BE pathways have been developed in conjunction with regulatory bodies. More Info
